|
Contribution of peripheral immune dysregulation to Alzheimer's disease |
1 R03 AG070506-01 |
|
NIA |
2021 |
|
Development of Nav1.1 Enhancers to Treat Alzheimer's Disease |
1 R44 AG071137-01A1 |
|
NIA |
2021 |
|
LRP1-tau interactions and Alzheimer Disease |
1 RF1 AG073236-01 |
|
NIA |
2021 |
|
Safety and Tolerability Studies for an Anti-Fibrin P2 Monoclonal Antibody for the Treatment of Alzheimer's Disease |
1 U01 AG073125-01 |
|
NIA |
2021 |
|
Investigating spatial representation in hippocampal entorhinal circuit of knock in Alzheimers model |
5 F31 AG069500-02 |
|
NIA |
2021 |
|
Defective lysosomal membrane fission mediates axonal lysosome accumulation in dystrophic neurites in Alzheimer's disease. |
5 K76 AG060001-03 |
|
NIA |
2021 |
|
Discovery of functionally selective Alzheimer's disease therapeutics |
5 R01 AG055072-05 |
|
NIA |
2021 |
|
Targeting neuroinflammation in AD with novel CX3CR1 agonists |
5 R01 AG062557-03 |
|
NIA |
2021 |